Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10059996 | 0.91 | — | — | |
| SCHEMBL10060006 | 0.89 | CSF1R (0.31) | — | |
| SCHEMBL1688263 | 0.87 | PTPN1 (0.35) | FFAR1HPGD | |
| SCHEMBL1688289 | 0.85 | FFAR1 (0.31) | FFAR1HPGD | |
| SCHEMBL1688226 | 0.84 | FFAR1 (0.39) | FFAR1 | |
| SCHEMBL10060015 | 0.82 | — | — | |
| SCHEMBL10059998 | 0.82 | PDE4A (0.31) | — | |
| SCHEMBL10060014 | 0.81 | — | — | |
| SCHEMBL1688306 | 0.79 | PTPN1 (0.39) | FFAR1 | |
| SCHEMBL1688287 | 0.79 | FFAR1 (0.31) | FFAR1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9072758-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-07-07 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-9040525-B2 | Cyclic amide derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| EP-2703393-A1 | CYCLIC AMIDE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2014-03-05 | — | — | EP | disclosed |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2014-02-27 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| WO-2012046869-A1 | CYCLIC AMIDE DERIVATIVE | 持田製薬株式会社 (JP) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266839-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | FFAR1 27/4885HPGD 3933/4885 |
| US-20140057871-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR4A1 | FFAR1 29/4885HPGD 4035/4885 |
| US-20150225392-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | FFAR1 25/4885HPGD 3909/4885 |
| US-20130203739-A1 | CYCLIC AMIDE DERIVATIVE | GPR119, NR0B1, NR2C2 | FFAR1 26/4885HPGD 3920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.